Skip to main content
. 2011 Mar 15;203(6):791–797. doi: 10.1093/infdis/jiq130

Table 1.

Characteristics of Patients who Achieved Viral Suppression and Characteristics of the First Successful Treatment following Detection of 69 Insertion or Q151M

Mutation, patient Year of detection Log10 HIV-1 RNA level at detection, copies/mL CD4+ cell count at detection, cells/μL CDC stage NRTI mutations at detection Majora NNRTI mutations at detection Majora PI mutations at detection Year of first successful treatment Successful treatment Year of loss of follow-up
69 insertion
1 1995 4.4 50 C M41L, 69 insertion, L210W, T215Y 2003 TDF EFV ddI 2009
2 1995 4.2 118 B M41L, 69 insertion, K70R, M184V, L210W, T215Y Y188C 1999 NFV ZDV 3TC 2009
3 1997 5.9 32 C M41L, 69 insertion, L210W, T215Y M46L, V82A, L90M 2001b
4 1997 3.3 472 B M41L, 69 insertion, M184I, T215Y 1997 SQV RTV NVP D4T 2009
5 1997 4.3 315 C M41L, 69 insertion, T215Y I84V 2000 LPV IDV D4T 3TC 2009
6 1999 3.1 180 B M41L, 69 insertion, L210W, T215Y M46I, T74P, I84V, L90M 2001 LPV EFV ddI 3TC 2009
7 1999 5.1 139 C M41L, 69 insertion, M184I, T215Y M46L, V82A, I84V 2002 EFV ddI ABC 2009
8 2001 4.2 415 B D67N, 69 insertion, K70R, K219Q 2004 RTV EFV ATV 3TC 2009
9 2002 4.8 542 B M41L, 69 insertion, T215Y Y181C M46I, G48V, I84V, N88S, L90M 2009
10 2003 5.7 13 B M41L, 69 insertion, L74V, L210W, T215Y L100I, K103N M46I, L76V, V82F, L90M 2003b
11 2004 4.8 198 B M41L, 69 insertion, M184V, L210W, T215Y M46I, I84V, L90M 2005 LPV EFV ZDV 3TC 2009
12 2004 5.1 367 C M41L, 69 insertion, L210W, T215Y M46L, V82A, L90M 2009
13 2007 2.9 358 B M41L, 69 insertion, M184V, L210W, T215Y K103N I54L, I84V, L90M 2008 TDF RAL ETV ABC 3TC 2009
Q151M
1 1995 5.4 160 A V75I, F77L, Y115F, F116Y, Q151M Q58E 2001b
2 1996 5.7 50 C F77L, F116Y, Q151M G48V, L90M 1997b
3 1996 4.2 100 C D67N, K70R, F77L, Q151M, T215F, K219E V108I 2000b
4 1996 3.5 162 B F116Y, Q151M, 1999 NFV D4T 3TC 2009
5 1996 4.4 133 C K65R, V75I, F77L, Y115F, F116Y, Q151M, K219Q 2008 TDF RTV RAL MVC ETV DRV ZDV 3TC 2009
6 1997 5.2 75 C M41L, A62V, V75I, F77L, F116Y, Q151M, M184V 1998b
7 1997 2.6 464 A D67N, Q151M, K219Q 2001b
8 1997 3.6 61 C Q151M, M184V 2001b
9 1997 3.8 476 C D67N, F116Y, Q151M Q58E 1997 IDV D4T 3TC 2009
10 1998 5.1 15 C A62V, V75I, F77L, F116Y, Q151M, M184V K103N M46L, G48V, V82A 2003b
11 1998 5.0 8 C M41L, D67N, F77L, F116Y, Q151M, M184V, L210W, T215Y M46I, V82A 2000b
12 1998 3.9 412 B A62V, K65R, V75I, F77L, Y115F, F116Y, Q151M, M184V D30N 1999 SQV RTV EFV D4T ABC 2007b
13 1999 5.8 5 C D67N, Q151M V82A, I84V, L90M 2000b
14 1999 5.3 23 C D67N, K70R, F116Y, Q151M, M184V, K219E V82A, L90M 2007 RTV RAL ETV DRV 3TC 2009
15 2000 5.3 36 C M41L, D67N, K70R, Q151M, M184V, T215F, K219E K103N, V108I I54L, V82A, L90M 2002b
16 2000 4.9 481 B A62V, V75I, F77L, F116Y, Q151M 2002 LPV EFV ZDV ABC 3TC 2009
17 2001 2.5 259 C A62V, F116Y, Q151M, M184V, M46I 2002 EFV D4T 3TC 2003b
18 2001 4.7 229 A A62V, V75I, F77L, F116Y, Q151M I84V, L90M 2003 LPV EFV APV 3TC 2009
19 2001 5.0 253 C A62V, K65R, D67N, V75I, F77L, Y115F, F116Y, Q151M, M184V, K219E D30N, M46I, I54M 2002 SQV NVP LPV 2009
20 2002 4.8 77 B K65R, K70R, V75I, F77L, Y115F, F116Y, Q151M, K219E K101E, Y181C, G190A M46I, V82A 2004 TDF RTV ETV ABC 2009
21 2003 3.9 191 C D67N, K70R, F116Y, Q151M, M184V, K219Q K103N M46I, Q58E, V82F, L90M 2006b
22 2003 3.0 5 B A62V, D67N, K70R, V75I, F77L, F116Y, Q151M, M184V, K219E K103N, V108I I50V, V82A, L90M 2004 TPV TDF T20 LPV DDI ZDV APV 3TC 2009
23 2004 4.5 84 B D67N, K70R, Y115F, F116Y, Q151M, M184V, K219Q Y181C, Y188L M46I, V82A 2006 TPV TDF RTV RAL ZDV 3TC 2009
24 2004 3.9 461 B F116Y, Q151M, M46I, L90M 2007 RTV DRV 2008b
25 2006 4.8 773 A F116Y, Q151M K103N, Y188L 2006 TDF RTV FTC ATV 2009

NOTE. Viral suppression was defined as 2 consecutive viral loads <50 copies/mL. 3TC, lamivudine; ABC, abacavir; APV, amprenavir; CDC, Centers for Disease Control and Prevention; D4T, stavudine; ddI, didanosine; DRV, darunavir; EFV, efavirenz; ETV, etravirine; HIV-1, human immunodeficiency virus type 1; IDV, indinavir; LPV, lopinavir; MVC, maraviroc; NFV, nelfinavir; NNRTI, nonnucleoside reverse transcriptase inhibitor; NRTI, nucleoside reverse transcriptase inhibitor; NVP, nevirapine; PI, protease inhibitor; RAL, raltegravir; RTV, ritanovir; SQV, saquinavir; T20, enfuvirtide; TDF, tenofovir; TPV, tipranavir; ZDV, zidovudine.

a

Mutations printed in bold on the International AIDS Society-USA list [12].

b

Year of death.